Life Science Newsletter
We’re sharing the June 2026 edition of our newsletter, covering the key regulatory developments in pharmaceuticals, medical devices and pharmacies, along with the most relevant shifts in health-related litigation. Central topics include Anvisa’s updated position on biosimilar interchangeability, the new VigiMed reporting manual, and progress integrating the SNCR with e-prescribing systems.
The newsletter also covers Anvisa’s public call to review technovigilance rules, the reorganization of medical-device petitions to cut the regulatory backlog, the new regulation of pharmacists’ role in palliative care, and the court ruling upholding vaccination services in pharmacies. The edition closes with the slowdown in private-health litigation following Supreme Court and STJ rulings, the new mandatory phase of the DUIMP for imports, and Anvisa’s consultation on the risk model used in health inspections. Together, these developments point to an increasingly technical and demanding regulatory agenda, with direct implications for compliance and risk management across the sector.